BAY-876, reported as a highly selective and potent GLUT1 inhibitor with an IC50 value of 2 nM as determined by indirect measurement [9], did not exhibit any growth inhibitory effect toward triple-negative breast cancer cells at 3 μM [27]. The gene discussed is SLC2A1; the disease is triple-negative breast carcinoma.